Global Immune Checkpoint Inhibitors Market - 2022-2029

Market Overview

The global immune checkpoint inhibitors market was valued at US$ 31,150.29 million in 2021 and is estimated to reach US$ 132,427.41 million by 2029, growing at a CAGR of 14.58% during the forecast period (2022-2029).

The immune checkpoint inhibitor is a drug made of antibodies that unleashes an immune system attack on cancer cells. Checkpoint inhibitors seek to overcome one of cancer's primary defenses against an immune system attack. Checkpoint inhibitors block normal proteins in cancer cells or the proteins in T cells. The result is removing the blinders that prevented T cells from recognizing them as cancerous, leading to an immune system assault on them.

Market Dynamics

The increasing demand for these immune checkpoint inhibitors, positive results in clinical trials, the increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and demand for immune checkpoint inhibitor devices drive market growth.

The global market for immune checkpoint inhibitors is primarily driven by the surge in demand for immune checkpoint inhibitor drugs in the healthcare industry, the rising number of product launches, positive results from clinical trials, and the many advantages over traditional chemotherapy alone. Various drugs in the clinical stage are showing good results in the treatment of various cancers. For instance, in Oct 2021, AstraZeneca' HIMALAYA phase III trial reported positive high-level results. The single dose of tremelimumab and Imfinzi showed a clinically significant overall survival benefit compared with sorafenib for 1st line treatment for unresectable hepatocellular carcinoma patients who haven't gotten systemic therapy. This new dose is known as the STRIDE regimen.

Various latest technological advancements are taking place, and the number of immune checkpoint inhibitors drug launches is increasing, increasing the demand as well. For instance, in Jun 2022, Roche announced the approval of Tecentriq (atezolizumab) for treating non-small cell lung cancer by the European Commission. Tecentriq is an adjuvant treatment that follows full resection and chemotherapy (platinum-based) for non-small cell lung cancer patients with high recurrence risk with PD-L1>50% tumor expression.

High costs associated with immune checkpoint inhibitors therapy will hamper the market's growth.

The high cost of therapies related to checkpoint inhibitors will restrain the market growth. According to the Journal of Clinical Pathways report published in Dec 2021, titled "Cost of extended use of immune checkpoint inhibitors in first-line non-small cell lung cancer," the average cost of immune checkpoint inhibitors is around $148,431. Cost of nivolumab/ipilimumab were around $544,696.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the industry, preparing and implementing backup plans as soon as possible for business operations is crucial. Various collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Jan 2022, AstraZeneca collaborated with Scorpion Therapeutics to research, develop and market precision medicines against the hard-to-target cancer proteins, potentially transforming the oncology treatment.

Segment Analysis

The programmed death receptor 1 inhibitor (PD-1) drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The programmed death receptor 1 inhibitor (PD-1) segment is the highest market holder in the global immune checkpoint inhibitors market. The programmed death receptor 1 inhibitor (PD-1) share accounted for the largest market because of its novel, innovative drug launches, an increasing number of pipelines and increasing prevalence of cancer. PD-1 is a checkpoint protein on the T cells (immune cells), which plays the role of an "off switch" that prevents T cells from attacking the body's other cells. It controls it at the time of its attachment with PD-L1, a kind of protein on a few normal and cancerous cells. When the binding occurs, the T-cell gets the message not to kill the cell. Few cancerous cells have a huge amount of PD-L1, which helps them to hide from immune attacks easily. The monoclonal antibodies targeting PD-1 inhibit the binding of PD-1 with PD-L1, ultimately increasing the immune response against cancerous cells. According to the WHO report 2022, cancer caused approximately ten million deaths globally, making it the major cause globally in 2020. The most common reason for cancer death was lung cancer accounting for around 1.80 million deaths. The novel development of these PD-1 inhibitors will benefit various cancer treatments. Increasing regulatory approvals of these PD-1 inhibitors are increasing market growth. For instance, in Aug 2021, GlaxoSmith Kline announced the approval of Jemparli (dostarlimab), a PD-1 immune checkpoint inhibitor for patients with advanced endometrial cancer and mismatch repair deficient recurrence.

Geographical Analysis

North America holds the largest market share of the global immune checkpoint inhibitors market.

North America dominates the global immune checkpoint inhibitors market, primarily attributed to the increasing number of partnerships or collaborations between companies, the rising demand for immune checkpoint inhibitor drugs, and novel studies. Furthermore, factors including growing expenditure on research and development and the increasing incidence of cancer will likely enhance the growth of the region's immune checkpoint inhibitors market.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments are taking place based in this region. For instance, in Sep 2022, AstraZeneca announced the approval of Imfinzi (durvalumab) by the United States Food and Drug Administration for treating metastatic or locally advanced biliary tract cancer patients with chemotherapy. This approval was based on a phase III trial of TOPAZ-1, where Imfinzi and chemotherapy minimized the death risk by 20% compared to chemotherapy alone.

Competitive Landscape

The immune checkpoint inhibitors market is highly competitive with local and global companies. AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc, Key players contributing to the market's growth Ono Pharmaceutical Co., Kite Pharma, Inc (Gilead company), F. Hoffmann-La Roche AG and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Apr 2020, Kite, Gilead Company and oNKo-innate announced their collaboration for research in cancer immunotherapy. Both companies entered in 2-year collaboration to support the development of next-gen drug therapies and engineered cell therapies focusing on natural killer cells (NK).

AstraZeneca PLC:

Overview:

AstraZeneca is a science-led, bio-pharmaceutical company that researches, develops and markets prescription medicines. It was established in 1999 and is headquartered in Cambridge, United Kingdom.

Product Portfolio:

Imfinzi (Durvalumab): This is an immune checkpoint inhibitor, a human immunoglobulin G1 monoclonal antibody used as immunotherapy for certain cancers. It inhibits the interaction between programmed cell death ligand 1 with programmed death receptor 1.

Key Development: In Aug 2022, AstraZeneca announced that it had completely acquired TeneoTwo Inc. This acquisition includes TeneoTwo's TNB-486, evaluated in B-cell non-Hodgkin lymphoma, phase I clinical stage CD19/CD3 T-cell engager.

The global immune checkpoint inhibitors market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.